Findings

What do systematic reviews say?

8 questions · 8 findings · 4 reviews · Schizophrenia

Sort:Best matchNewest Highest certainty Download CSV

No studies found 0 · 0%GRADE not reported 2 · 25%Very low 1 · 12.5%Low 4 · 50%Moderate 1 · 12.5%High 0 · 0%

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Risk for at least one adverse event per patient · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Risk for at least one adverse event per patient · patients with schizophrenia

FLUPHENAZINE showed no clear difference in adverse effects‐at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (moderate certainty).

1 finding from 1 review

Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.79 [0.58, 1.07]
1 study · 65 participants
Moderate

HALOPERIDOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Risk for at least one adverse event per patient · patients with schizophrenia

It is very uncertain whether HALOPERIDOL changes adverse effects ‐ at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (very low certainty).

1 finding from 1 review

Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.97 [0.69, 5.66]
5 studies · 158 participants
Very low

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Risk for at least one adverse event per patient · patients with schizophrenia

Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ at least one adverse effect compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 0.83 [0.36, 1.95]
2 studies · 165 participants
Low

FLUPENTHIXOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

1 finding from 1 review

Flupenthixol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
no estimate extracted
0 studies · 0 participants
GRADE not reported

FLUPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

FLUPHENAZINE may leads to higher adverse effects‐movement disorders‐at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Fluphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 2.11 [1.41, 3.15]
3 studies · 971 participants
Low

HALOPERIDOL vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

HALOPERIDOL may leads to higher adverse effects ‐ movement disorders ‐ At least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Haloperidol versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 1.64 [1.22, 2.21]
5 studies · 170 participants
Low

PERPHENAZINE vs LOW‐POTENCY ANTIPSYCHOTIC DRUGS

Adverse effects ‐ movement disorders ‐ At least one movement disorder · patients with schizophrenia

Comparison 1: PERPHENAZINE showed no clear difference in adverse effects ‐ movement disorders ‐ at least one movement disorder compared with LOW‐POTENCY ANTIPSYCHOTIC DRUGS (low certainty).

1 finding from 1 review

Perphenazine versus low‐potency first‐generation antipsychotic drugs for schizophrenia 2014 · Cochrane Headline outcomes only
RR 15.62 [0.94, 260.49]
1 study · 69 participants
Low